James P. Boylan - Jun 10, 2025 Form 4 Insider Report for Immunome Inc. (IMNM)

Role
Director
Signature
/s/ Sandra Stoneman, Attorney-in-Fact
Stock symbol
IMNM
Transactions as of
Jun 10, 2025
Transactions value $
$0
Form type
4
Date filed
6/12/2025, 05:00 PM
Previous filing
Feb 13, 2025
Next filing
Jun 27, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Boylan James P Director C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL /s/ Sandra Stoneman, Attorney-in-Fact 2025-06-12 0001953094

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMNM Director Stock Option (right to buy) Award $0 +18.9K $0.00 18.9K Jun 10, 2025 Common Stock 18.9K $9.57 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities.
F2 The option vests in four quarterly installments, commencing from June 10, 2025 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to Mr. Boylan's continuous service with the Company on each respective vesting date.